fashion -WSS

fashion

author：comprehensive 2025-10-02 01:08:21 - browse：927

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How are insurers handling Leqembi and related scans?

leisure time

WSS

Why does health care cost so much? A reading guide

Cell therapy fails to slow type 1 diabetes, but safety is established

Inflation cooled significantly in June, bringing price hikes close to normal levels

Getting Alzheimer's drug Leqembi to patients can be a challenge

Health care needs a new profession: neuroimaging counseling

Cholera vaccine supply gets boost as demand surges globally

explore

fashion

hotspot

Continuity nursing helped my family in our darkest PICU moments

After traumatic brain injury, life support decisions can use more time

How to save PrEP access — and even expand it

Grail's uphill battle for Medicare to cover its cancer screening test

Walensky prepares to leave CDC — and Congress — behind

More tobacco lobbyists active in statehouses

Walensky prepares to leave CDC — and Congress — behind

Exact Sciences stock tumbles despite strong cancer detection sales

Hepatitis C has a cure — but many Americans still lack access to it

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

hotspot

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Vermont grapples with historic flooding as more rainstorms head for Northeast

Antibody drugs appear effective. Now can we make enough of them?

Companies helping big Covid

How are insurers handling Leqembi and related scans?

leisure time

leisure time

leisure time

Wikipedia